Home・Elenco Azioni・Denali Therapeutics Inc

Denali Therapeutics Inc

Chiusa

SettoreSettore sanitario

24.8 2.65

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.4

Massimo

24.9

Metriche Chiave
By Trading Economics
Entrata	894K -128M
Vendite	3.6M 3.6M
EPS	-0.68
Margine di Profitto	-3,539.206
Dipendenti	503
EBITDA	1.6M -124M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+44.46% upside

Dividendi
By Acuity
Utili prossimi	4 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	218M 3.9B
Apertura precedente	22.15
Chiusura precedente	24.8

Notizie sul Sentiment di mercato

By Acuity

25%

75%

73 / 340 Classifica in Healthcare

Denali Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ago 2026, 22:46 UTC

Denali Therapeutics Inc's shares are higher in after-market trading, reflecting a cumulative gain since Monday's close. No specific news was identified for this movement.

20 ago 2026, 19:16 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today, reflecting broader market trends. The stock has declined since Wednesday amid volatility in biotech and small-cap indices.

19 ago 2026, 20:02 UTC

Correlated Moves

DNLI is higher Wednesday, recovering with the SPDR S&P Biotech ETF.

17 ago 2026, 19:36 UTC

Correlated Moves

Denali Therapeutics Inc is trading higher today, supported by gains in the biotechnology sector. The stock remains near its 20-day moving average.

13 ago 2026, 19:36 UTC

News

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

12 ago 2026, 19:36 UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

11 ago 2026, 23:21 UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

10 ago 2026, 19:36 UTC

Correlated Moves

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

7 ago 2026, 19:26 UTC

Social Media

News

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

6 ago 2026, 21:03 UTC

News

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

3 ago 2026, 19:46 UTC

Correlated Moves

News

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

31 lug 2026, 20:02 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

30 lug 2026, 19:18 UTC

Correlated Moves

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

29 lug 2026, 22:01 UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

28 lug 2026, 18:46 UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

27 lug 2026, 19:56 UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

24 lug 2026, 19:26 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

22 lug 2026, 17:46 UTC

Correlated Moves

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

21 lug 2026, 17:36 UTC

Correlated Moves

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

20 lug 2026, 23:41 UTC

Correlated Moves

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.

Confronto tra pari

Modifica del prezzo

Denali Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.46% in crescita

Previsioni per 12 mesi

Media 36 USD 44.46%

Alto 42 USD

Basso 26 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Denali Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Denali Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

73 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.